NeuVax vaccination reduces tumor growth in mouse models
SAN RAMON, Calif.—Biopharmaceutical company Galena Biopharma Inc. recently shared preclinical data regarding its NeuVax program at the Progress in Vaccination Against Cancer Conference. NeuVax is a first-in-class, HER2-directed cancer immunotherapy currently being assessed for its ability to prevent breast cancer recurrence after standard-of-care treatment in the adjuvant setting. The study in question featured HLA-A2 transgenic mice that were immunized with NeuVax (E75) mixed with recombinant mouse GM-CSF. CD8+ T cells from the spleens of HLA-A2 transgenic immunized mice were transferred to NSG (NOD/SCID/IL2Rγnull) mice with human ovarian or pancreatic tumors which were HER2-positive and HLA-A2-positive. NeuVax vaccination led to a specific, delayed-type hypersensitivity reaction and the induction of E75-specific CD8+ T cells that express PD-1. Growth rate for both ovarian and pancreatic tumors was significantly reduced in models of NSG mice that received the CD8+ T cells from NeuVax-immunized mice, compared to those receiving the cells from control mice.